BioShockers'  Instablog

Send Message is a recently created biotech investing website that is focused on finding high-potential, low-price, and legitimate biotech/pharma companies. The great majority of stocks we will do write-ups on will be on one of three exchanges, NASDAQ, AMEX, or NYSE. Occasionally, we will... More
  • Alexza Pharmaceuticals -- A Rare Find 0 comments
    May 12, 2010 4:43 PM | about stocks: ALXA

    Alexza is a rare find in the biotech sector, with low outstanding shares, a revolutionary drug delivery system, and a drug (AZ-004) w/ an upcoming PDUFA date of Oct. 11, 2010.

    Alexza's drug delivery system is called the "Stacatto system". The Stacatto system is a heat package with a stainless steel substrate, onto which a thin film of unformulated drug is coated. When the patient draws a normal breath through the Staccato system, the substrate surface instantaneously heats to create a condensation aerosol. The patient inhales perfectly sized particles of pure drug down into the narrower, more vascularized tissue of the deep lung, allowing fast and more complete absorption into the bloodstream. This system has a use for potentially many different conditions.

    Alexza has a well-diversified pipeline of drugs: AZ-004 (Acute Treatment of Agitation associated with Schizophrenia or Bipolar Disorder - PDUFA date of Oct. 11, 2010), AZ-001 (Migraine Headache - end-of-phase 2 meeting w/ FDA completed), AZ-104 (Migraine Headache - phase 2b trial completed), AZ-003 (Breakthrough Pain - phase 1 study completed), AZ-002 (Acute Panic Attacks - P2a study completed, but inconclusive results), and AZ-007 (Insomnia - phase 1 trial completed w/ positive results).

    AZ-004 successfully completed both phase 3 trials (one for acute agitation in schizophrenia patients, the other for acute agitation in bipolar patients), and an NDA was filed near the end of 2009. In Feb. 2010, Alexza announced that they had formed a collaboration with Biovail to develop and commercialize AZ-004. The initial market size for AZ-004 is $300-$500M.

    As far as analyst coverage goes, JMP Securities has given a target price for ALXA of $12/shr, and multiple other analysts have initiated coverage in the past year as well.

    As you can see, Alexza is a very promising company w/ a drug going up for approval in October, along w/ possible share price appreciation in anticipation of the PDUFA date.

    As always, please read our disclaimer in our bio before investing in any stock that we alert. is a recently created investment website, with a fully functional FDA Calendar, Daily Blog, and Research on Biotech stocks.

    Disclosure: Long ALXA

    Stocks: ALXA
Back To BioShockers' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

Latest Comments

Most Commented
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.